# OnCo record paper-tropion-breast01-china-cohort-esmo-open-2026 (paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/key-papers/paper-tropion-breast01-china-cohort-esmo-open-2026/>
  a schema:ScholarlyArticle ;
  onco:kind "paper" ;
  schema:identifier "paper-tropion-breast01-china-cohort-esmo-open-2026" ;
  schema:name "TROPION-Breast01 China cohort: datopotamab deruxtecan versus chemotherapy in previously treated HR-positive, HER2-negative breast cancer"@en ;
  schema:description "Among the 83 patients enrolled in mainland China, datopotamab deruxtecan roughly doubled the time before the cancer grew compared with chemotherapy, with fewer severe side effects, in line with the global trial."@en ;
  schema:url <https://onco.cc/key-papers/paper-tropion-breast01-china-cohort-esmo-open-2026/> ;
  schema:dateModified "2026-09-21"^^xsd:date ;
  schema:citation <https://doi.org/10.1016/j.esmoop.2026.108538>, <https://pubmed.ncbi.nlm.nih.gov/42727418/>, <https://clinicaltrials.gov/study/NCT05104866> ;
  schema:sameAs <https://doi.org/10.1016/j.esmoop.2026.108538> ;
  schema:datePublished "2026"^^xsd:gYear ;
  schema:author "Wang S, Zhang Q, Jiang Z, et al." ;
  onco:cancers <https://onco.cc/cancers/breast-hr-positive/> ;
  onco:drugs <https://onco.cc/drugs/datopotamab-deruxtecan/> ;
  onco:companies <https://onco.cc/companies/astrazeneca/>, <https://onco.cc/companies/daiichi-sankyo/> ;
  onco:terms <https://onco.cc/terms/pfs/>, <https://onco.cc/terms/os/> ;
  onco:trials <https://onco.cc/trials/tropion-breast01/> ;
  onco:people <https://onco.cc/people/xu-binghe/>, <https://onco.cc/people/aditya-bardia/> ;
  onco:journals <https://onco.cc/journals/esmo-open/> .